(151) Microglia-targeting nanocarriers reduce hypothalamic inflammation in cancer-related cachexia

Introduction: Hypothalamic inflammation plays a pivotal role in appetite dysregulation across various pathological conditions, including cancer cachexia. However, delivering anti-inflammatory agents to microglia, key mediators of hypothalamic inflammation, remains challenging due to the unsurmountable blood-brain barrier (BBB). To overcome this challenge, dual peptide-functionalized polymeric nanocarriers capable of both BBB penetration and microglial targeting were engineered for systemic delivery of IRAK4 inhibitors to treat hypothalamic inflammation.